Fady Kadifa, MD
Pulmonary Disease · Laguna Hills, CANPI 1083711014
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (55.2%), consulting fees and education — rather than concentrated in one kind of arrangement. 30 manufacturers reported payments, led by Edwards Lifesciences at 31.1% of the total. Reporting peaked in 2021 at $1,525 and has fallen 87.8% since, to $185 in 2025.
Across 97 payments — averaging $39.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Edwards Lifesciences$1K
- Verathon Inc.$500
- GSK$486
- Boehringer Ingelheim$395
- Inari Medical, Inc.$206
- Stryker$129
- plus $939 from 24 others
What the payments were for
- Consulting fees$1,70044%
- Food & beverage$2,12655%
- Education$291%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Edwards Lifesciences | 1 | $1,200 |
| Verathon Inc. | 1 | $500 |
| GSK | 37 | $486 |
| Boehringer Ingelheim | 14 | $395 |
| Inari Medical, Inc. | 2 | $206 |
| Stryker | 1 | $129 |
| AstraZeneca | 6 | $106 |
| Sanofi | 3 | $74 |
| Grifols USA, LLC | 3 | $73 |
| Insmed, Inc. | 3 | $72 |
| Johnson & Johnson | 3 | $64 |
| Mylan Specialty L.p. | 3 | $59 |
| Pulmonx Corporation | 2 | $58 |
| Vifor Pharma, Inc. | 2 | $48 |
| Regeneron Healthcare Solutions, Inc. | 1 | $36 |
| Intuitive Surgical | 1 | $32 |
| Otsuka America Pharmaceutical, Inc. | 1 | $31 |
| Philips North America LLC | 1 | $30 |
| Mallinckrodt Hospital Products Inc. | 1 | $29 |
| Resmed Corp | 1 | $29 |
| Portola Pharmaceuticals, LLC | 1 | $28 |
| Advanced Respiratory, Inc | 1 | $23 |
| Genentech USA, Inc. | 1 | $22 |
| AbbVie | 1 | $20 |
| Ambu Inc. | 1 | $19 |
| Teva Pharmaceuticals USA, Inc. | 1 | $19 |
| Merck | 1 | $18 |
| Novartis | 1 | $18 |
| Circassia Inc. | 1 | $17 |
| Shire North American Group Inc | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,855 in reported general payments places this provider in the 65th percentile of 1,261 pulmonary disease providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 140 | $77,804 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 65 | $71,328 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 63 | $46,658 |
| Spiriva RespimatTiotropium Bromide | 55 | $44,220 |
| Breo ElliptaFluticasone/Vilanterol | 65 | $28,688 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 20 | $15,486 |
| EliquisApixaban | 24 | $12,516 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 20 | $12,020 |
| SymbicortBudesonide/Formoterol Fumarate | 39 | $11,646 |
| DuleraMometasone/Formoterol | 24 | $10,821 |
| Incruse ElliptaUmeclidinium Bromide | 24 | $7,972 |
| BreynaBudesonide/Formoterol Fumarate | 39 | $7,878 |
| Advair HfaFluticasone Propion/Salmeterol | 23 | $7,156 |
| Wixela InhubFluticasone Propion/Salmeterol | 73 | $6,563 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 47 | $4,330 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta | $486 | $127,382187 claims |
| Boehringer IngelheimStiolto Respimat, Spiriva Respimat | $395 | $122,025195 claims |
| AstraZenecaBreztri Aerosphere, Bevespi Aerosphere, Symbicort | $106 | $70,324122 claims |
| MerckDulera | $18 | $10,82124 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,261 pulmonary disease providers in California.
Other pulmonary disease in Laguna Hills
- Samuel LouieSacramento$2.8M
- Shyamsunder SubramanianTracy$1.5M
- Toby MaherLos Angeles$1.3M
- Rajkumar DasguptaPasadena$930K
- Hoang leFountain Valley$814K
- Kevin FussellEncinitas$788K
- Revati ShreeniwasStanford$726K
- David PhamWestminster$571K
- Vijay BalasubramanianFresno$529K
- Victor TapsonLos Angeles$514K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.